Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $74,118.66 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Andrea Difabio sold 1,342 shares of the business’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $74,118.66. Following the completion of the transaction, the insider directly owned 7,301 shares of the company’s stock, valued at approximately $403,234.23. This trade represents a 15.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrea Difabio also recently made the following trade(s):

• On Tuesday, March 10th, Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $60.11, for a total value of $156,706.77.

Xenon Pharmaceuticals Trading Down 4.6%

Xenon Pharmaceuticals stock opened at $55.23 on Monday. The stock has a market cap of $4.59 billion, a PE ratio of -12.67 and a beta of 0.91. The stock has a 50-day moving average price of $43.71 and a 200 day moving average price of $41.96. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the prior year, the firm posted ($0.84) EPS. On average, equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Cinctive Capital Management LP increased its position in Xenon Pharmaceuticals by 1.1% during the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock worth $1,045,000 after purchasing an additional 263 shares during the last quarter. Arizona State Retirement System raised its stake in Xenon Pharmaceuticals by 1.8% during the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock worth $774,000 after purchasing an additional 334 shares during the period. State of Wyoming boosted its holdings in shares of Xenon Pharmaceuticals by 30.4% in the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 350 shares during the last quarter. Quarry LP boosted its holdings in shares of Xenon Pharmaceuticals by 25.0% in the 3rd quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 500 shares during the last quarter. Finally, Altfest L J & Co. Inc. grew its stake in shares of Xenon Pharmaceuticals by 6.5% during the 4th quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 501 shares during the period. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on XENE shares. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Wells Fargo & Company boosted their price target on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the company an “overweight” rating in a report on Tuesday, March 10th. HC Wainwright increased their price target on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Morgan Stanley set a $97.00 price objective on Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, Chardan Capital raised Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus target price of $71.94.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.